

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 March 2002 (21.03.2002)

PCT

(10) International Publication Number
WO 02/022664 A3

(51) International Patent Classification⁷: **C12N 15/34**,
C07K 14/01, A61K 39/12, C07K 16/08, C12N 15/86,
G01N 33/569, C12Q 1/70

(74) Agent: **KEUS, Jacobus, A.R.**; Intervet International B.V.,
Patent Department, Wim de Köverstraat 35, NL-5831 AN
Boxmeer (NL).

(21) International Application Number: PCT/EP01/10679

(81) Designated States (*national*): AE, AG, AL, AU, BA, BB,
BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE,
GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR,
LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PH, PL,
RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU,
ZA.

(22) International Filing Date:
14 September 2001 (14.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00203186.2 15 September 2000 (15.09.2000) EP

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:
— with international search report


(71) Applicant (*for all designated States except US*): **AKZO
NOBEL N.V.** [NL/NL]; Velperweg 76, NL-6824 BM Ar-
nhem (NL).

(88) Date of publication of the international search report:
9 October 2003

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): **VLAK, Justinus,
Maria** [NL/NL]; Nieuwe Veenendaalseweg 214, NL-3911
Mr Rhenen (NL). **VAN HULTEN, Maria, Cornelia, Wil-
helmina** [NL/NL]; Salverdaplein 10, NL-6701 DB Wa-
geningen (NL).

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ANTIGENIC PROTEINS OF SHRIMP WHITE SPOT SYNDROME VIRUS AND USES THEREOF



(57) Abstract: The present invention relates to antigenic proteins derived from White Spot Syndrome virus having an estimated size of 19 kDa (VP 19) or 13 kDa (VP13), to the use of these proteins in vaccines and to vaccines on the basis of these proteins. Furthermore, the invention relates to antibodies against these proteins and to the use of antibodies in vaccines, to nucleic acid sequences encoding these proteins and to their use in vaccines. Also, the invention relates to the use of said proteins in the manufacture of a vaccine for prophylaxis and/or treatment of White Spot Syndrome in crustaceans, to vector vaccines and to diagnostic kits comprising said nuclei acids or antibodies.



WO 02/022664 A3